Cribriform-Morular Variant of Papillary Thyroid Carcinoma | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

Cribriform-Morular Variant of Papillary Thyroid Carcinoma

key information

source: Pathology, research and practice

year: 2015

authors: Pradhan D, Sharma A, Mohanty S K


Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) is a rare morphologic entity. This tumor is usually associated with familial adenomatous polyposis (FAP), but rarely may be sporadic. This neoplasm commonly occurs in young females. The majority of patients present with gradually enlarging painless neck mass. There is no specific imaging finding of CMV-PTC, and the diagnosis is exclusively made on pathologic examination. A multitude of cytologic features of CMV-PTC are described, which includes hypercellularity, cribriform pattern, papillary arrangement of tall columnar cells, morules, spindle cells, clear and ground-glass nuclei, hyaline material, hemosiderin-laden histiocytes, and absence of colloid in the background. CMV-PTC is histologically characterized by the papillary growth of tall columnar cells, cribriform pattern without colloid, spindle cells, squamoid morules, and nuclear clearing. The immunoreactivity for beta-catenin and biotin-positive nuclear clearing may indicate CMV-PTC. Total thyroidectomy for familial or lobectomy for sporadic cases is usually the treatment for CMV-PTC. It carries a better prognosis than the other aggressive variants of papillary thyroid carcinoma. In this review, we discuss the current knowledge on CMV-PTC and its clinical relevance.

organization: Medicine Core Diagnostics, University of Pittsburgh Medical Center

DOI: 10.1016/j.prp.2015.04.011

read more full text source

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.